Amikacin Inj.Sol 500mg/2ml (EU CTD Available) & 1g/4ml (EU CTD Available: Q3 2021)

Product Description

Amikacin Solution for Injection 
Reference Product: Briklin® / BRISTOL-MYERS SQUIBB
Description: Amikacin sulfate is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli, species of indole-positive and indole-negative Proteus, Providencia species, Klebsiella species, Enterobacter species, Serratia species, and Acinetobacter species. 
Dossier Status: EU CTD Available (500mg/2ml) & Q3 2021 (1g/4ml)
Stability Studies: Zone II / Zone IVb
Shelf life: Two (2) years
Batch Size: 18,180 vials (500mg/2ml) & 9,090 vials (1g/4ml)
Pack Size: BT x 1 vial

ANFARM HELLAS S.A.

  • GR
  • 2015
    On CPHI since
Specifications
  • Selling Points
    International Approvals/Standards
  • Supplied from
    Greece

ANFARM HELLAS S.A.

  • GR
  • 2015
    On CPHI since

More Products from ANFARM HELLAS S.A. (4)

  • Apixaban F.C. Tabs 2.5mg/tab & 5mg/tab  (under development)

    Product Apixaban F.C. Tabs 2.5mg/tab & 5mg/tab (under development)

    Apixaban Film Coated Tablets 2.5mg & 5mg
    Reference Product: Eliquis® / Bristol-Myers Squibb/Pfizer
    Description: Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ...
  • Azithromycin Pd.Sol.Inf 500mg/Vial (EU CTD Available)

    Product Azithromycin Pd.Sol.Inf 500mg/Vial (EU CTD Available)

    Azithromycin 500mg/Vial Powder for Solution for Infusion Reference Product: Zithromax® / PFIZER 
    Description: Azithromycin as powder for solution for infusion is indicated for the treatment of community-acquired pneumonia due to susceptible microorganisms in adult patients where initial intraveno...
  • Brivaracetam Oral Solution 10mg/ml (EU CTD Available: Q4 2022)

    Product Brivaracetam Oral Solution 10mg/ml (EU CTD Available: Q4 2022)

    Brivaracetam 10mg/ml Oral Solution
    Reference Product: Briviact® / UCB
    Description: Brivaracetam is an antiepileptic agent which is indicated as adjunctive therapy in the treatment of partial onsetseizures with or without secondary generalization in adults, adolescents and children from 4 years o...
  • Brivaracetam Sol. Inf 10mg/ml (5ml Vial) (EU CTD Available: Q3 2022)

    Product Brivaracetam Sol. Inf 10mg/ml (5ml Vial) (EU CTD Available: Q3 2022)

    Brivaracetam 10mg/ml (5ml Vial) Solution for Injection/Infusion
    Reference Product: Briviact® / UCB
    Description: Brivaracetam is an antiepileptic agent which is indicated as adjunctive therapy in the treatment of partial onsetseizures with or without secondary generalization in adults, adolescents and ch...

ANFARM HELLAS S.A. resources (2)